AU Patent

AU2022215189C1 — New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making

Assigned to F Hoffmann La Roche AG · Expires 2025-08-07 · 1y expired

What this patent protects

#$%^&*AU2022215189C120250807.pdf##### Abstract The present invention relates to a process for preparation of 7-(4,7-diazaspiro[2,5]octan-7-yl)-2-(2,8 dimethylimidazo[1,2-b]pyridazine-6-yl)pyrido[1,2-a]pyrimidin-4-one useful as pharmaceutically active compounds Abstract The …

USPTO Abstract

#$%^&*AU2022215189C120250807.pdf##### Abstract The present invention relates to a process for preparation of 7-(4,7-diazaspiro[2,5]octan-7-yl)-2-(2,8 dimethylimidazo[1,2-b]pyridazine-6-yl)pyrido[1,2-a]pyrimidin-4-one useful as pharmaceutically active compounds Abstract The present invention relates to a process for preparation of 7-(4,7-diazaspiro[2,5]octan-7-yl)-2-(2,8- dimethylimidazo[1,2-b]pyridazine-6-yl)pyrido[1,2-alpyrimidin-4-one usetul as pharmaceutically 2022215189 09 2022 Aug active compounds

Drugs covered by this patent

Patent Metadata

Patent number
AU2022215189C1
Jurisdiction
AU
Classification
—
Expires
2025-08-07
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.